A selection of compounds
from a proprietary library, based on chemical
diversity and various biological activities, was evaluated as potential
inhibitors of the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) in a phenotypic-based screening assay. A compound based
on a 2-phenylquinoline scaffold emerged as the most promising
hit, with EC
50
and CC
50
values of 6 and 18 μM,
respectively. The subsequent selection of additional analogues, along
with the synthesis of ad hoc derivatives, led to compounds that maintained
low μM activity as inhibitors of SARS-CoV-2 replication and
lacked cytotoxicity at 100 μM. In addition, the most promising
congeners also show pronounced antiviral activity against the human
coronaviruses HCoV-229E and HCoV-OC43, with EC
50
values
ranging from 0.2 to 9.4 μM. The presence of a 6,7-dimethoxytetrahydroisoquinoline
group at the C-4 position of the 2-phenylquinoline core gave
compound
6g
that showed potent activity against SARS-CoV-2
helicase (nsp13), a highly conserved enzyme, highlighting a potentiality
against emerging HCoVs outbreaks.